Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
about
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves.The effect of care setting in the delivery of high-value colon cancer carePhase 1/2 study of orteronel (TAK-700), an investigational 17,20-lyase inhibitor, with docetaxel-prednisone in metastatic castration-resistant prostate cancer.Prognosis Related to Metastatic Burden Measured by ¹⁸F-Fluorocholine PET/CT in Castration-Resistant Prostate Cancer.Activation of AKR1C1/ERβ induces apoptosis by downregulation of c-FLIP in prostate cancer cells: A prospective therapeutic opportunity.Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma.The Potential of MicroRNAs as Prostate Cancer Biomarkers.Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.Importance of cycles of chemotherapy and postdocetaxel novel therapies in metastatic castration-resistant prostate cancer.Emerging perspectives in prostate cancer: Insights from the 4th Asia Pacific Prostate Cancer Conference.(11)C-Choline PET/CT in castration-resistant prostate cancer patients treated with docetaxel.
P2860
Q26852544-BFF257DB-E382-41C2-860B-FFC51D576173Q28555163-34F26795-5087-4871-8966-A21156E19460Q35077470-C6949CAC-DB28-457D-B871-670E2ACDB2E3Q35328550-70DCE139-F39F-454B-ACB5-C2827038E645Q35582133-5E36CDE5-012C-4BE5-A489-CEA9B636CEA4Q35793871-F21508B4-511B-41BF-A019-CF5C87282129Q35809973-E2268AD3-6D2A-4AD7-929F-8C08A7750885Q37722656-4D733151-CEDD-49DE-8425-38E2848E9769Q38710305-12316155-8955-4979-A36B-47F9C123839CQ38938883-75B534D5-2303-4D0D-B7E4-6285F05A6663Q39063102-6FA63A05-C355-4F02-AC17-53B6CF2627A4Q40755361-E4FB525E-9623-4ED7-A094-496DB0F54E0BQ42666209-90EFB277-0EE4-4569-BE6E-59B0FBBB6683Q48139886-2F19858B-5AA3-4BFC-BA9E-1656ADE008A9
P2860
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
description
2013 nî lūn-bûn
@nan
2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Systemic therapy in men with m ...... e cancer: a systematic review.
@ast
Systemic therapy in men with m ...... e cancer: a systematic review.
@en
Systemic therapy in men with m ...... e cancer: a systematic review.
@nl
type
label
Systemic therapy in men with m ...... e cancer: a systematic review.
@ast
Systemic therapy in men with m ...... e cancer: a systematic review.
@en
Systemic therapy in men with m ...... e cancer: a systematic review.
@nl
prefLabel
Systemic therapy in men with m ...... e cancer: a systematic review.
@ast
Systemic therapy in men with m ...... e cancer: a systematic review.
@en
Systemic therapy in men with m ...... e cancer: a systematic review.
@nl
P2093
P1433
P1476
Systemic therapy in men with m ...... e cancer: a systematic review.
@en
P2093
C Walker-Dilks
D A Loblaw
E Winquist
Genitourinary Cancer Disease S ...... Program in Evidence-Based Care
P304
P356
10.1016/J.CLON.2013.03.002
P577
2013-04-12T00:00:00Z